Share ownership VYNE Therapeutics Inc.

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-10 pm EST			5-day change	1st Jan Change
3.430 ^USD	-12.50%		-0.87%	+2.39%

Jan. 06	VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo	CI
Dec. 23	VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor	MT

Share class: VYNE Therapeutics Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	14,751,433	13,512,520 ( 91.60 %)	0	91.60 %

Major shareholders: VYNE Therapeutics Inc.

Name	Equities	%	Valuation
Eventide Asset Management LLC 9.452 %	1,394,336	9.452 %	4 M $
Cormorant Asset Management LP 9.452 %	1,394,336	9.452 %	4 M $
Citadel Securities GP LLC 8.049 %	1,187,413	8.049 %	4 M $
Access Industries, Inc. (New York) 7.569 %	1,116,585	7.569 %	3 M $
DSC Advisors LP 4.721 %	696,465	4.721 %	2 M $
David Domzalski 3.227 %	476,061	3.227 %	1 M $
Palo Alto Investors LP 3.020 %	445,434	3.020 %	1 M $
Vanguard Global Advisers LLC 3.007 %	443,518	3.007 %	1 M $
Exome Asset Management LLC 2.396 %	353,434	2.396 %	1 M $
LifeSci Fund Management LLC 1.820 %	268,485	1.820 %	794 716 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	50.06%
Other	9.03%
Individuals	6.26%
State Street Corp.	0.11%
Unknown	34.54%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	59.07%
Individuals	6.26%
Canada	0.02%

Based on 1000 largest holdings

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-02-26 - Q4 2024 Earnings Release (Projected)

More about the company